Prostate cancer is the most frequently diagnosed cancer in North American men and, despite improvements in early detection due to prostate-specific antigen (PSA) screening, it remains the second leading cause of cancer-related death among men. Standard treatment for localized disease includes radical prostatectomy, external beam radiation therapy (EBRT), and brachytherapy, which are often combined with hormone therapy in high risk patients. These treatments are successful in controlling organconfined disease; however if tumors recur, the disease is typically systemic and hormone therapy remains the only treatment option. While hormone therapy is initially efficacious, patients eventually progress to androgen-independent disease, which is incurable. Immune-based treatments such as cancer vaccines are emerging as a treatment option for those patients with hormone-refractory disease, however the results to date from clinical trials, while promising, do not yet warrant the adoption of immunotherapy as standard of care. Further progress will require a deeper understanding of the interactions between the immune system and prostate cancer. Although we have some understanding of the natural host response to prostate cancer at the time of diagnosis, far less is known regarding the state of tumor immunity at the completion of standard treatments and beyond, despite the fact that this is the immunological context in which immunebased treatments must operate if the goal is to prevent or delay recurrence. One can imagine that standard treatments, by causing tumor cell death in an inflammatory context, must have an impact on the host immune response. Do standard treatments enhance or inhibit host immunity to prostate cancer? Does host immunity have a significant influence on clinical outcomes? If standard treatments fail, does this in part reflect a failure of the immune system? And finally, how can we best enhance the immune response to tip the balance in favor of tumor stabilization or rejection? We begin this discussion by reviewing the concepts, technical issues, and evidence concerning the effect of standard treatments on tumor-specific immunity in prostate cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F.J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J.P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis J., Andre, F., Delaloge, S., Tursz, T., Kroemer, G., and Zitvogel, L. 2007. Toll like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13: 1050–1059
Aragon-Ching, J.B., Williams, K.M., and Gulley, J.L. 2007. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front. Biosci. 12: 4957–4971
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Mattelaer, J., Lopez Torecilla, J., Pfeffer, J.R., Lino Cutajar, C., Zurlo, A., and Pierart, M. 2002. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.[comment]. Lancet 360: 103–106
Burch, P.A., Breen, J.K., Buckner, J.C., Gastineau, D.A., Kaur, J.A., Laus, R.L., Padley, D.J., Peshwa, M.V., Pitot, H.C., Richardson, R.L., Smits, B.J., Sopapan, P., Strang, G., Valone, F.H., and Vuk-Pavlovic, S. 2000. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin.Cancer Res. 6: 2175–2182
Casiano, C.A., Ochs, R.L., and Tan, E.M. 1998. Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ. 5: 183–190
Chakraborty, M., Abrams, S.I., Camphausen, K., Liu, K., Scott, T., Coleman, C.N., and Hodge, J.W. 2003. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. 170: 6338–6347
Chakraborty, M., Abrams, S.I., Coleman, C.N., Camphausen, K., Schlom, J., and Hodge, J.W. 2004. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64: 4328–4337
Ciernik, I.F., Romero, P., Berzofsky, J.A., and Carbone, D.P. 1999. Ionizing radiation enhances immunogeniCity of cells expressing a tumor-specific T-cell epitope. Int. J. Radiat. Oncol. Biol. Phys. 45: 735–741
Demaria, S., Ng, B., Devitt, M.L., Babb, J.S., Kawashima, N., Liebes, L., and Formenti, S.C. 2004. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58: 862–870
Demaria, S., Bhardwaj, N., McBride, W.H., and Formenti, S.C. 2005a. Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 63: 655–666
Demaria, S., Kawashima, N., Yang, A.M., Devitt, M.L., Babb, J.S., Allison, J.P., and Formenti, S.C. 2005b. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11: 728–734
DiPaola, R.S., Plante, M., Kaufman, H., Petrylak, D.P., Israeli, R., Lattime, E., Manson, K., and Schuetz, T. 2006. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J. Transl. Med. 4: 1
Drake, C.G., Doody, A.D., Mihalyo, M.A., Huang, C.T., Kelleher, E., Ravi, S., Hipkiss, E.L., Flies, D.B., Kennedy, E.P., Long, M., McGary, P.W., Coryell, L., Nelson, W.G., Pardoll, D. M., and Adler, A.J. 2005. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7: 239–249
Fossa, A., Alsoe, L., Crameri, R., Funderud, S., Gaudernack, G., and Smeland, E.B. 2004. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol. Immunother. 53: 431–438
Garnett, C.T., Palena, C., Chakraborty, M., Tsang, K.Y., Schlom, J., and Hodge, J.W. 2004. Sublethal irradiation of human tumor cells modulates phe-notype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64: 7985–7994
Gulley, J.L., Arlen, P.M., Bastian, A., Morin, S., Marte, J., Beetham, P., Tsang, K.Y., Yokokawa, J., Hodge, J.W., Menard, C., Camphausen, K., Coleman, C.N., Sullivan, F., Steinberg, S.M., chlom, J., and Dahut, W. 2005a. Combining a ecombinant cancer vaccine with standard definiive radiotherapy in patients with localized pros te cancer. Clin. Cancer Res. 11: 3353–3362
Gulley, J.L., Todd, N., Dahut W., Schlom, J., and Arlen, P. 2005b. A phase II study of PROSTVAC-VF vaccine, and the role of GM- CSF, in patients with metastatic androgen insensitive prostate cancer (AIPC). J. Clin. Oncol. 23: Supplement, 2504
Heath, W.R., Belz, G.T., Behrens, G.M., Smith, C.M., Forehan, S.P., Parish, I.A., Davey, G.M., Wilson, N.S., Carbone, F.R., and Villadangos, J.A. 2004. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199: 9–26
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M.A., Lallas, C.D., Dahm, P., Niedzwiecki, D., Gilboa, E., and Vieweg, J. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109: 409–417
Heymann, J.J., Benson, M.C., O'Toole, K.M., Malyszko, B., Brody, R., Vecchio, D., Schiff, P.B., Mansukhani, M.M., and Ennis, R.D. 2007. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J. Clin. Oncol. 25: 77–84
Hoeppner, L.H., Dubovsky, J.A., Dunphy, E.J., and McNeel, D.G. 2006. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun. 6: 1
Hoffmann, T.K., Donnenberg, A.D., Finkelstein, S.D., Donnenberg, V.S., Friebe-Hoffmann, U., Myers, E.N., Appella, E., DeLeo, A.B., and Whiteside, T.L. 2002. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264–272) peptide in the circulation of patients with head and neck cancer. Cancer Res. 62: 3521–3529
Jager, D., Karbach, J., Pauligk, C., Seil, I., Frei, C., Chen, Y.T., Old, L.J., Knuth, A., and Jager, E. 2005. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun. 5: 11–17
Jager, E., Chen, Y.T., Drijfhout, J.W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L.J., and Knuth, A. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompat-ibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265–270
Javid, B., MacAry, P.A., and Lehner, P.J. 2007. Structure and function: heat shock proteins and adaptive immunity. J. Immunol. 179: 2035–2040
Kaufman, H.L., and Divgi, C.R. 2005. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination. Clin. Cancer Res. 11: 6757–6762
Kaufman, H.L., Wang, W., Manola, J., DiPaola, R.S., Ko, Y.J., Sweeney, C., Whiteside, T.L., Schlom, J., Wilding, G., and Weiner, L.M. 2004. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22: 2122–2132
Kudo-Saito, C., Schlom, J., Camphausen, K., Coleman, C.N., and Hodge, J.W. 2005. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin. Cancer Res. 11: 4533–4544
Laverdiere, J., Nabid, A., De Bedoya, L.D., Ebacher, A., Fortin, A., Wang, C.S., and Harel, F. 2004. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J. Urol. 171: 1137–1140
Le Bon, A., Etchart, N., Rossmann, C., Ashton, M., Hou, S., Gewert, D., Borrow, P., and Tough, D.F. 2003. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4: 1009–1015
Lim, Y., Lee, D.Y., Lee, S., Park, S.Y., Kim, J., Cho, B., Lee, H., Kim, H.Y., Lee, E., Song, Y.W., and Jeoung, D.I. 2002. Identification of autoantibodies associated with systemic lupus erythematosus. Biochem. Biophys. Res. Commun. 295:119–124
Lodge, P.A., Jones, L.A., Bader, R.A., Murphy, G.P., and Salgaller, M.L. 2000. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res. 60: 829–833
Ludgate, C.M., Bishop, D.C., Pai, H., Eldridge, B., Lim, J., Berthelet, E., Blood, P., Piercy, G.B., and Steinhoff, G. 2005. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation. Int. J. Radiat. Oncol. Biol. Phys. 62: 1309–1315
Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., and Lord, E.M. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174: 7516–7523
McBride, W.H., Chiang, C.S., Olson, J.L., Wang, C.C., Hong, J.H., Pajonk, F., Dougherty, G.J., Iwamoto, K.S., Pervan, M., and Liao, Y.P. 2004. A sense of danger from radiation. Radiat. Res. 162: 1–19
McNeel, D.G., Nguyen, L.D., Storer, B.E., Vessella, R., Lange, P.H., and Disis, M.L. 2000. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J. Urol. 164: 1825–1829
Melero, I., Arina, A., Murillo, O., Dubrot, J., Alfaro, C., Perez-Gracia, J.L., Bendandi, M., and Hervas-Stubbs, S. 2006. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin. Cancer Res. 12: 2385–2389
Mercader, M., Bodner, B.K., Moser, M.T., Kwon, P.S., Park, E.S., Manecke, R.G., Ellis, T.M., Wojcik, E.M., Yang, D., Flanigan, R.C., Waters, W.B., Kast, W.M., and Kwon, E.D. 2001. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. USA. 98: 14565–14570
Miles, A.K., Rogers, A., Li, G., Seth, R., Powe, D., McArdle, S.E., McCulloch, T.A., Bishop, M.C., and Rees, R.C. 2007. Identification of a novel prostate cancer-associated tumor antigen. Prostate 67: 274–287
Nesslinger, N.J., Sahota, R.A., Stone, B., Johnson, K., Chima, N., King, C., Rasmussen, D., Bishop, D., Rennie, P.S., Gleave, M., Blood, P., Pai, H., Ludgate, C., and Nelson, B.H. 2007. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin. Cancer Res. 13: 1493–1502
Newcomb, E.W., Demaria, S., Lukyanov, Y., Shao, Y., Schnee, T., Kawashima, N., Lan, L., Dewyngaert, J.K., Zagzag, D., McBride, W.H., and Formenti, S.C. 2006. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin. Cancer Res. 12: 4730–4737
Okada, T., Akada, M., Fujita, T., Iwata, T., Goto, Y., Kido, K., Okada, T., Matsuzaki, Y., Kobayashi, K., Matsuno, S., Sunamura, M., and Kawakami, Y. 2006. A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin. Cancer Res. 12: 191–197
Oliver, R.T., Joseph, J.V., and Gallagher, C.J. 1995. Castration-induced lymphocytosis in prostate cancer: possible evidence for gonad/thymus endocrine interaction in man. Urol. Int. 54: 226–229
Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., Camphausen, K., Luiten, R.M., de Ru, A.H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F.A., Spits, H., Schlom, J., van Veelen, P., and Neefjes, J.J. 2006. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203: 1259–1271
Roden, A.C., Moser, M.T., Tri, S.D., Mercader, M., Kuntz, S.M., Dong, H., Hurwitz, A.A., McKean, D.J., Celis, E., Leibovich, B.C., Allison, J.P., and Kwon, E.D. 2004. Augmentation of T cell levels and responses induced by androgen deprivation. J. Immunol. 173: 6098–6108
Scanlan, M.J., Chen, Y.T., Williamson, B., Gure, A.O., Stockert, E., Gordan, J.D., Tureci, O., Sahin, U., Pfreundschuh, M., and Old, L.J. 1998. Characterization of human colon cancer antigens recognized by autologous antibodies. Int. J. Cancer 76: 652–658
Simons, J.W., and Sacks, N. 2006. Granulocyte macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol. Oncol. 24: 419–424
Simons, J.W., Mikhak, B., Chang, J.F., DeMarzo, A.M., Carducci, M.A., Lim, M., Weber, C.E., Baccala, A.A., Goemann, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H.B., Piantadosi, S., Marshall, F.F., and Nelson, W.G. 1999. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete gran-ulocyte-macrophage colony-stimulating factorusing ex vivo gene transfer. Cancer Res. 59: 5160–5168
Small, E.J., Rini, B., Higano, C., Redfern, C., Nemunaitis, J., Valone, F., Kylstr, J., and Schellhammer, P.F. 2003. A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-inde-pendent prostate cancer (AiPCa). Proc. Am. Soc. Clin. Oncol. 22: 382–388
Small, E.J., Schellhammer, P.F., Higano, C.S., Redfern, C.H., Nemunaitis, J.J., Valone, F.H., Verjee, S.S., Jones, L.A., and Hershberg, R.M. 2006. Placebo-controlled phase III trial of immu-nologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24: 3089–3094
Small, E.J., Sacks, N., Nemunaitis, J., Urba, W.J., Dula, E., Centeno, A.S., Nelson, W.G., Ando, D., Howard, C., Borellini, F., Nguyen, M., Hege, K., and Simons, J.W. 2007a. Granulocyte macrophage colony-stimulating factor–secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13: 3883–3891
Small, E.J., Tchekmedyian, N.S., Rini, B.I., Fong, L., Lowy, I., and Allison, J.P. 2007b. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13: 1810–1815
Tomlins, S.A., Laxman, B., Dhanasekaran, S.M., Helgeson, B.E., Cao, X., Morris, D.S., Menon, A., Jing, X., Cao, Q., Han, B., Yu, J., Wang, L., Montie, J.E., Rubin, M.A., Pienta, K.J., Roulston, D., Shah, R.B., Varambally, S., Mehra, R., and Chinnaiyan, A.M. 2007. Distinct classes of chromosomal rearrangements create onco-genic ETS gene fusions in prostate cancer. Nature 448: 595–599
Tsai, C.H., Hong, J.H., Hsieh, K.F., Hsiao, H.W., Chuang, W.L., Lee, C.C., McBride, W.H., and Chiang, C.S. 2006. Tetracycline-regulated intra-tumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer. Cancer Gene Ther. 13: 1082–1092
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647
Vesalainen, S., Lipponen, P., Talja, M., and Syrjanen, K. 1994. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 30A: 1797–1803
Vonderheide, R.H., Domchek, S.M., Schultze, J.L., George, D.J., Hoar, K.M., Chen, D.Y., Stephans, K.F., Masutomi, K., Loda, M., Xia, Z., Anderson, K.S., Hahn, W.C., and Nadler, L.M. 2004. Vaccination of cancer patients against telomerase induces functional antitu-mor CD8+ T lymphocytes. Clin. Cancer Res. 10: 828–839
Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J.E., Pienta, K.J., Sanda, M.G., Kantoff, P.W., Rubin, M.A., Wei, J.T., Ghosh, D., and Chinnaiyan, A.M. 2005. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353: 1224–1235
Wilson, C.A., Mrose, S.A., and Thomas, D.W. 1995. Enhanced production of B lymphocytes after castration. Blood 85: 1535–1539
Zhou, Y., Toth, M., Hamman, M.S., Monahan, S.J., Lodge, P.A., Boynton, A.L., and Salgaller, M.L. 2002. Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. Biochem. Biophys. Res. Commun. 290: 830–838
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V
About this chapter
Cite this chapter
Nesslinger, N.J., Pai, H.H., Ludgate, C.M., Nelson, B.H. (2008). Effects of Standard Treatments on the Immune Response to Prostate Cancer. In: Hayat, M.A. (eds) General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. Methods of Cancer Diagnosis, Therapy, and Prognosis, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8442-3_37
Download citation
DOI: https://doi.org/10.1007/978-1-4020-8442-3_37
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-8441-6
Online ISBN: 978-1-4020-8442-3
eBook Packages: MedicineMedicine (R0)